Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04375527 | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | terminated | Phase 2 | 3 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05744128 | CD8 Minibody Repeatability Study(PRETZCEL) | terminated | Phase 2 | 3 | ImaginAb, Inc.INDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT05457842 | A Study to Find the Best Dose of ASP5354 to Show Lymph Nodes in People With Breast Cancer or Melanoma During Surgery | terminated | Phase 2 | 1 | Astellas Pharma IncINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT01217411 | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2024 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma | terminated | Phase 2 | 315 | Novartis PharmaceuticalsINDUSTRY | 15 | Oct 9, 2024 | clinicaltrials |
| NCT00863330 | Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 14 | Wake Forest University Health SciencesOTHER | 1 | Oct 3, 2024 | clinicaltrials |
| NCT03476174 | Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | terminated | Phase 2 | 1 | Ralph HaukeOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05200143 | Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma | terminated | Phase 2 | 4 | Providence Health & ServicesOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | terminated | Phase 2 | 15 | Karyopharm Therapeutics IncINDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors | terminated | Phase 1 / Phase 2 | 37 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT04924413 | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | terminated | Phase 2 | 9 | Quanli GaoOTHER_GOV | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04655157 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma(QUAD01) | terminated | Phase 1 / Phase 2 | 2 | Jason J. Luke, MDOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT02621515 | Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases(CA209-322) | terminated | Phase 2 | 7 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT00199342 | A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma | terminated | Phase 1 / Phase 2 | 5 | Kyowa Kirin, Inc.INDUSTRY | 1 | May 3, 2024 | clinicaltrials |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | terminated | Phase 1 / Phase 2 | 1 | iOx TherapeuticsINDUSTRY | 3 | Apr 24, 2024 | clinicaltrials |
| NCT05050006 | ITIL-168 in Advanced Melanoma(DELTA-1) | terminated | Phase 2 | 29 | Instil BioINDUSTRY | 3 | Apr 16, 2024 | clinicaltrials |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab | terminated | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04899921 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT00003552 | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04455503 | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | terminated | Phase 1 / Phase 2 | 15 | Evaxion Biotech A/SINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05060003 | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04337931 | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma | terminated | Phase 2 | 45 | Apexigen America, Inc.INDUSTRY | 2 | Feb 13, 2024 | clinicaltrials |
| NCT04894994 | FLX475 in Combination With Ipilimumab in Advanced Melanoma | terminated | Phase 2 | 6 | RAPT Therapeutics, Inc.INDUSTRY | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 6 | Arkadiusz Z. Dudek, MDOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04785365 | Long-Term Follow-Up Study of Patients Receiving ATL001 | terminated | Phase 2 | 1 | Achilles Therapeutics UK LimitedINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02425306 | Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma(Mel63; CHAMP) | terminated | Phase 1 / Phase 2 | 48 | Craig L Slingluff, JrOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 4 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT02831933 | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma(ENSIGN) | terminated | Phase 2 | 11 | Eric Bernicker, MDOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03430947 | Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases(RadioCoBRIM) | terminated | Phase 2 | 20 | Technische Universität DresdenOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT02740920 | Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker | terminated | Phase 2 | 9 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 25, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT02748564 | Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT02203604 | High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery | terminated | Phase 2 | 9 | CINJRegulatoryOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT00104884 | FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | terminated | Phase 2 | 4 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jun 28, 2023 | clinicaltrials |
| NCT01559818 | A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001 | terminated | Phase 1 / Phase 2 | 10 | Immodulon Therapeutics LtdINDUSTRY | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03637803 | Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | terminated | Phase 1 / Phase 2 | 63 | 4D pharma plcINDUSTRY | 1 | Jun 1, 2023 | clinicaltrials |
| NCT01995344 | TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment(METILDA) | terminated | Phase 2 | 2 | The Christie NHS Foundation TrustOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05234437 | A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma | terminated | Phase 2 | 1 | QBiotics Group LimitedINDUSTRY | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02054520 | Immunotherapy Study for Patients With Stage IV Melanoma | terminated | Phase 2 | 47 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04834973 | A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma | terminated | Phase 1 / Phase 2 | 3 | QBiotics Group LimitedINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT00667953 | Study of Temzolomide and Gleevec in Advanced Melanoma | terminated | Phase 1 / Phase 2 | 32 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 / Phase 2 | 118 | Calithera Biosciences, IncINDUSTRY | 1 | Mar 17, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02052193 | Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study | terminated | Phase 2 | 8 | University Hospital TuebingenOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05219578 | RTX-224 Monotherapy in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Rubius TherapeuticsINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT02414750 | Vemurafenib Plus Cobimetinib in Metastatic Melanoma(REPOSIT) | terminated | Phase 2 | 78 | Netherlands Working Group on Immunotherapy of OncologyOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT00945269 | Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma | terminated | Phase 1 / Phase 2 | 3 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT00145158 | Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma | terminated | Phase 1 / Phase 2 | 23 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 10, 2022 | clinicaltrials |
| NCT00145145 | Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 7, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Dec 4, 2024source: clinicaltrials